15.450 articles found

New clinical application of medical composition

XIAODAN WANG.

· 2009-03-09

Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.

LeWitt PA, Ondo WG, Van Lunen B, Bottini PB.

Clin Neuropharmacol · 2009-03-01

DOI: 10.1097/wnf.0b013e31816d91f9PMID: 18978491

Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.

Gunzler SA, Pavel M, Koudelka C, Carlson NE, Nutt JG.

Clin Neuropharmacol · 2009-03-01

DOI: 10.1097/wnf.0b013e3181684c22PMID: 18978495

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, FIRST-STEP Study Group.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22343PMID: 19058133

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, TEMPO Open-label Study Group.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22402PMID: 19086083

Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation.

Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22390PMID: 19097175

Improved asymmetry of gait in Parkinson's disease with DBS: gait and postural instability in Parkinson's disease treated with bilateral deep brain stimulation in the subthalamic nucleus.

Johnsen EL, Mogensen PH, Sunde NA, Østergaard K.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22419PMID: 19097189

Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22108PMID: 19117369

Levodopa use and sleep in patients with dementia with Lewy bodies.

Molloy S, Minett T, O'Brien JT, McKeith IG, Burn DJ.

Mov Disord · 2009-03-01

DOI: 10.1002/mds.22411PMID: 19191343

Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism.

Kim JH, Byun HJ.

Hum Psychopharmacol · 2009-03-01

DOI: 10.1002/hup.1009PMID: 19204914

Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson's disease and mutations in PARK2 or PARK8 genes.

Barsottini OG, Felício AC, Aguiar Pde C, Godeiro-Junior C, Shih MC, Hoexter MQ, Bressan RA, Ferraz HB, Andrade LA.

Arq Neuropsiquiatr · 2009-03-01

DOI: 10.1590/s0004-282x2009000100003PMID: 19330201

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK, Reisensburg Working Group for Tauopathies With Parkinsonism.

Eur J Neurol · 2009-03-01

DOI: 10.1111/j.1468-1331.2008.02513.xPMID: 19364361